Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Equities researchers at Wedbush cut their FY2018 earnings estimates for shares of Eiger Biopharmaceuticals in a research note issued to investors on Wednesday, December 5th. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings of ($3.60) per share for the year, down from their previous estimate of ($2.71). Wedbush currently has a “Buy” rating and a $55.00 price objective on the stock. Wedbush also issued estimates for Eiger Biopharmaceuticals’ Q4 2018 earnings at ($0.78) EPS, Q1 2019 earnings at ($0.67) EPS, Q2 2019 earnings at ($0.70) EPS, Q3 2019 earnings at ($0.73) EPS, Q4 2019 earnings at ($0.76) EPS, FY2019 earnings at ($2.86) EPS, FY2020 earnings at ($2.92) EPS, FY2021 earnings at ($2.54) EPS and FY2022 earnings at ($1.08) EPS.
A number of other research firms have also commented on EIGR. LADENBURG THALM/SH SH set a $28.00 price objective on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 17th. ValuEngine lowered Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Oppenheimer set a $26.00 price objective on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 18th. Finally, Zacks Investment Research lowered Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $29.71.
Shares of NASDAQ EIGR opened at $11.44 on Friday. The company has a market cap of $215.01 million, a PE ratio of -2.35 and a beta of 1.55. The company has a debt-to-equity ratio of 0.56, a quick ratio of 4.59 and a current ratio of 4.59. Eiger Biopharmaceuticals has a 1-year low of $7.46 and a 1-year high of $18.00.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Friday, November 9th. The biotechnology company reported ($1.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.43).
In other Eiger Biopharmaceuticals news, major shareholder Interwest Partners X. Lp sold 237,265 shares of the firm’s stock in a transaction on Thursday, October 18th. The stock was sold at an average price of $12.06, for a total transaction of $2,861,415.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Eldon C. Mayer III acquired 6,000 shares of the stock in a transaction on Wednesday, November 28th. The shares were bought at an average price of $10.07 per share, for a total transaction of $60,420.00. Following the purchase, the director now owns 7,500 shares in the company, valued at $75,525. The disclosure for this purchase can be found here. 7.90% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Eiger Biopharmaceuticals by 0.6% in the 3rd quarter. Jennison Associates LLC now owns 1,263,978 shares of the biotechnology company’s stock valued at $15,168,000 after purchasing an additional 7,477 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Eiger Biopharmaceuticals by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 450,456 shares of the biotechnology company’s stock valued at $5,406,000 after purchasing an additional 21,000 shares during the last quarter. 683 Capital Management LLC increased its stake in shares of Eiger Biopharmaceuticals by 51.2% in the 2nd quarter. 683 Capital Management LLC now owns 295,285 shares of the biotechnology company’s stock valued at $3,602,000 after purchasing an additional 100,000 shares during the last quarter. GMT Capital Corp bought a new position in shares of Eiger Biopharmaceuticals in the 2nd quarter valued at $3,459,000. Finally, Renaissance Technologies LLC increased its stake in shares of Eiger Biopharmaceuticals by 21.1% in the 3rd quarter. Renaissance Technologies LLC now owns 278,813 shares of the biotechnology company’s stock valued at $3,346,000 after purchasing an additional 48,584 shares during the last quarter. Institutional investors own 51.62% of the company’s stock.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.